首页 / 专利库 / 兽医学 / 人畜共患病 / 炭疽病 / 苯并咪唑并三嗪酮类化合物、制备方法及应用

苯并咪唑并三嗪类化合物、制备方法及应用

阅读:895发布:2022-01-11

专利汇可以提供苯并咪唑并三嗪类化合物、制备方法及应用专利检索,专利查询,专利分析的服务。并且本 发明 属于 杀菌剂 领域,公开了苯并咪唑并三嗪 酮 类化合物、制备方法及应用,该化合物的结构如式(I)所示:本发明涉及的化合物制备方法简便,具有防治 植物 病原 真菌 的效果,可应用于农业作为杀菌剂。,下面是苯并咪唑并三嗪类化合物、制备方法及应用专利的具体信息内容。

1.式(I)所示结构的苯并咪唑并三嗪类化合物,
其中,
R1选自C1-6烷基、取代C1-6烷基、苯基、取代苯基、苄基、取代苄基,所述的取代基团选自1-
3个卤素;
2
R选自氢、C1-6烷基、取代C1-6烷基,所述的取代基团选自1-3个卤素;
Y(n)中,n=1-3取代,Y(n)选自下列1-3个基团:卤素、C1-6烷基、取代C1-6烷基,所述的取代基团选自1-3个卤素。
2.根据权利要求1所述的苯并咪唑并三嗪酮类化合物,其特征在于:
R1选自C1-6烷基、苯基、苯甲基;
R2选自氢、C1-3烷基;
Y(n)中,n=1取代,Y(n)选自卤素、C1-3烷基。
3.根据权利要求2所述的苯并咪唑并三嗪酮类化合物,其特征在于:
R1选自甲基、乙基、丙基、异丙基、丁基、异丁基、苯基、苯甲基;
R2选自氢、甲基;
Y(n)选自氢、3-氯、4-氯、4-溴、4-氟、4-甲基。
4.根据权利要求3所述的苯并咪唑并三嗪酮类化合物,其特征在于其为如下所述化合物之一:
1-代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯、
1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯、
1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯、
1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯、
1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯、
1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯、
1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯、
1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯、
1-氧代-3对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯、
1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯、
1-氧代-3对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯、
1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯、
1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯、
1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯、
1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯、
1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯、
1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯、
1-氧代-3对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯、
1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯、
1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯、
1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯、
1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯、
1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯、
1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯、
1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯、
1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯、
1-氧代-3-苯基-4-甲基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯、
1-氧代-3-苯基-4-甲基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯。
5.一种制备权利要求1-4中任一项所述的苯并咪唑并三嗪酮类化合物,其特征在于按通式(A)表示的方法制备:
其中在上述各结构式中:
R1、R2、Y(n)均具有权利要求1-4中任一项所述的含义。
6.权利要求1-4中任一项所述的苯并咪唑并三嗪酮类化合物在防治植物病原真菌方面的应用。
7.根据权利要求6所述的应用,其特征在于权利要求1-4中任一项所述的苯并咪唑并三嗪酮类化合物在防治稻作物真菌病害水果作物真菌病害、蔬菜作物真菌病害方面的应用。
8.根据权利要求7所述的应用,其特征在于权利要求1-4中任一项所述的苯并咪唑并三嗪酮类化合物在防治水稻作物中由丝核菌属真菌引起的病害、水果作物中由葡萄孢属真菌引起的病害、蔬菜作物中由炭疽菌属真菌引起的病害。
9.根据权利要求8所述的应用,其特征在于权利要求1-4中任一项所述的苯并咪唑并三嗪酮类化合物在防治水稻纹枯病、草莓灰霉病、辣椒炭疽病方面的应用。

说明书全文

苯并咪唑并三嗪类化合物、制备方法及应用

技术领域

[0001] 本发明涉及苯并咪唑并三嗪酮类化合物、制备方法及其在防治植物病原真菌方面的应用,具有制备农药杀菌剂的用途。

背景技术

[0002] 苯并咪唑类化合物具有广泛的生物活性,如抗菌、除草、消炎、抗寄生虫、抗癌、抗病毒、镇痛等。以苯并咪唑环为分子骨架开发出的一系列高效低毒类杀菌剂,如多菌灵(carbendazim)、苯菌灵(benomyl)、麦穗宁(fuberidazole)、涕必灵(thiabendazole)和氰菌灵(cypendazole)等,为提高农作物产量和质量作出了卓越贡献。由于苯并咪唑类杀菌剂被长期高剂量使用,部分品种产生了抗药性(如多菌灵),故研发新型抗菌活性化合物作为苯并咪唑类杀菌剂的替代品种具有十分重要的意义。本专利通过在苯并咪唑环上引入取代苯肼基团,再进行环合,设计合成了一系列新型苯并咪唑并三嗪酮类化合物,这类化合物对植物病原真菌具有明显的杀菌活性。

发明内容

[0003] 本发明的目的在于提供苯并咪唑并三嗪酮类化合物。
[0004] 本发明的另一目的在于提供苯并咪唑并三嗪酮类化合物的制备方法。
[0005] 本发明的另一个目的在于提供上述化合物的应用。
[0006] 本发明的第一方面提供了一种具有通式(I)所示结构的苯并咪唑并三嗪酮类化合物,
[0007]
[0008] 在式(I)中,所述各个基团具有如下所述的定义:
[0009] R1选自C1-6烷基、取代C1-6烷基、苯基、取代苯基、苄基、取代苄基,所述的取代基团选自1-3个卤素;
[0010] R2选自氢、C1-6烷基、取代C1-6烷基,所述的取代基团选自1-3个卤素;
[0011] Y(n)中,n=1-3取代,Y(n)选自下列1-3个基团:卤素、C1-6烷基、取代C1-6烷基,所述的取代基团选自1-3个卤素。
[0012] 在式(I)中,所述各个基团具有如下所述的优选定义:
[0013] R1选自C1-6烷基、苯基、苯甲基;
[0014] R2选自氢、C1-3烷基;
[0015] Y(n)中,n=1取代,Y(n)选自卤素、C1-3烷基。
[0016] 在式(I)中,所述各个基团具有如下所述的进一步优选定义:
[0017] R1选自甲基、乙基、丙基、异丙基、丁基、异丁基、苯基、苯甲基;
[0018] R2选自氢、甲基;
[0019] Y(n)选自氢、3-氯、4-氯、4-溴、4-氟、4-甲基。
[0020] 在式(I)中,所述各个基团具有如下所述的特别优选定义:
[0021] 1-代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(A1)、
[0022] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(A2)、
[0023] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(A3)、
[0024] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(A4)、
[0025] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯(A5)、
[0026] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(A6)、
[0027] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(A7)、
[0028] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(A8)、
[0029] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(B1)、
[0030] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(B2)、
[0031] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(B3)、
[0032] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(B4)、
[0033] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(B5)、
[0034] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(B6)、
[0035] 1-氧代-3对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(B7)、
[0036] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(C1)、
[0037] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(C2)、
[0038] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(C3)、
[0039] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(C4)、
[0040] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯(C5)、
[0041] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(C6)、
[0042] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(C7)、
[0043] 1-氧代-3对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(C8)、
[0044] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(D1)、
[0045] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(D2)、
[0046] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(D3)、
[0047] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯(D4)、
[0048] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(D5)、
[0049] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(D6)、
[0050] 1-氧代-3对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(D7)、
[0051] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(E1)、
[0052] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(E2)、
[0053] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(E3)、
[0054] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(E4)、
[0055] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(E5)、
[0056] 1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(F1)、
[0057] 1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(F2)、
[0058] 1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(F3)、
[0059] 1-氧代-3-苯基-4-甲基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(G1)、
[0060] 1-氧代-3-苯基-4-甲基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(G2)。
[0061] 本发明的第二个方面提供了制备式(I)的苯并咪唑并三嗪酮类化合物的方法,该方法以式(II)的化合物与式(III)的氯甲酸酯反应,制备式(I)的苯并咪唑并三嗪酮类化合物,其反应方程式可用下述通式(A)表示:
[0062]
[0063] 其中在上述各结构式中:
[0064] R1、R2、Y(n)均具有如前所述的相应基团的定义。
[0065] 本发明的第三个方面涉及式(I)的苯并咪唑并三嗪酮类化合物在防治植物病原真菌方面的应用,可应用于农药领域,作为杀菌剂。
[0066] 本发明的式(I)的苯并咪唑并三嗪酮类化合物可以在植物保护中用于防治下列病原菌引起的作物真菌病害,但它不应视为是对本发明的任何限制:
[0067] 防治稻作物真菌病害:
[0068] 丝核菌属,如茄丝核菌Rhizoctonia solani,引起水稻纹枯病;
[0069] 防治水果作物真菌病害:
[0070] 葡萄孢属,如灰葡萄孢菌Botrytis cinerea,引起草莓灰霉病、葡萄灰霉病;
[0071] 防治蔬菜作物真菌病害:
[0072] 葡萄孢属,如灰葡萄孢菌Botrytis cinerea,引起茄科蔬菜灰霉病,如辣椒灰霉病、茄子灰霉病;
[0073] 炭疽菌属,如辣椒刺盘孢Colletotrichum capsici,引起辣椒炭疽病
[0074] 本发明的化合物特别适合于用于防治水稻作物真菌病害,如水稻纹枯病;防治水果作物真菌病害,如草莓灰霉病;防治蔬菜作物真菌病害,如辣椒炭疽病。
[0075] 有益效果:
[0076] 1、本发明专利所述的式(I)的苯并咪唑并三嗪酮类化合物的分子结构新颖,该结构式中含苯并咪唑并三嗪酮这一特征基团,同时含有苯基、甲酸酯基团。
[0077] 2、本发明专利所述的式(I)的苯并咪唑并三嗪酮类化合物的制备方法简便、原料易得、产率高。
[0078] 3、本发明专利所述的式(I)的苯并咪唑并三嗪酮类化合物表现出明显的抑制植物病原真菌的活性,具有作为农药杀菌剂的用途。

具体实施方式

[0079] 本发明的实质性特点可从下述实施例得以体现,但它不应视为是对本发明的任何限制。
[0080] 制备实施例
[0081] 实施例1:苯并咪唑并三嗪酮类化合物A1的制备
[0082] 在浴条件下,在50mL三口瓶中加入10mL四氢呋喃、4mmol化合物(II-A1)和1.8mL三乙胺,搅拌,缓慢滴加8mmol氯甲酸甲酯(III-A1),用TLC监控反应进程,反应完成后,过滤,收集滤液,减压蒸馏去除溶剂,再以乙酸乙酯溶解,用水洗涤,用无水硫酸镁干燥,过滤,蒸除部分溶剂,冷却结晶,过滤,干燥,得苯并咪唑并三嗪酮类化合物A1,其反应方程式如下:
[0083]
[0084] 采用实施例1的方法,制备了苯并咪唑并三嗪酮类化合物(I)中的A、B、C、D、E、F、G系列化合物:
[0085] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(A1):
[0086]
[0087] 无色晶体,收率33.3%,m.p.161.2-163.4℃;IR(KBr,cm-1)v:3304,2968,2869,1745,1565,1498,1364,747,738;1H NMR(400MHz,DMSO-d6)δ(ppm):8.00-7.93(m,1H),7.72-
7.65(m,1H),7.41-7.34(m,2H),7.29(dd,J=8.7,7.4Hz,2H),7.10(d,J=8.0Hz,2H),6.95(t,J=7.3Hz,1H),5.57(s,1H),5.18(s,1H),3.91(s,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):152.10,151.08,147.47,145.58,142.76,131.22,130.19,125.69(d,J=17.0Hz),
123.11,120.35,115.26,114.40,55.06,48.20;EI-MS,m/z(%):322(M+,77),277(75),220(16),145(10),130(12),118(5),105(45),90(10),77(100),51(10).
[0088] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(A2):
[0089]
[0090] 无色晶体,收率32.1%,m.p.177.1-179.3℃;IR(KBr,cm-1)v:3033,2985,2848,1
1740,1616,1594,1568,1497,1361,1265,1189,746,738;H NMR(400MHz,DMSO-d6)δ(ppm):
8.00-7.93(m,1H),7.72-7.65(m,1H),7.41-7.34(m,2H),7.29(t,J=8.0Hz,2H),7.10(d,J=8.0Hz,2H),6.95(t,J=7.3Hz,1H),5.57(s,1H),5.18(s,1H),4.36(q,J=7.1Hz,2H),
1.30(t,J=7.1Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.54,151.13,147.51,145.62,
142.77,131.23,130.19,125.66(d,J=16.5Hz),123.07,120.33,115.22,114.41,64.29,
48.16,14.58;EI-MS,m/z(%):336(M+,20),292(14),264(95),220(16),158(10),131(56),
105(50),90(12),77(100),51(10).
[0091] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(A3):
[0092]
[0093] 无色晶体,收率34.2%,m.p.161.4-162.9℃;IR(KBr,cm-1)v:3359,2959,2919,2848,1788,1709,1624,1596,1579,1451,1363,1253,1197,739;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(d,J=8.0Hz,1H),7.67(d,J=7.0Hz,1H),7.44-7.33(m,2H),7.29(t,J=
7.6Hz,2H),7.07(d,J=8.0Hz,2H),6.94(t,J=7.3Hz,1H),5.55(s,1H),5.17(s,1H),4.28
13
(t,J=6.4Hz,2H),1.76-1.62(m,2H),0.92(t,J=7.4Hz,3H);C NMR(101MHz,DMSO-d6)δ(ppm):151.59,151.15,147.50,145.64,131.23,130.17,125.65(d,J=16.4Hz),123.06,
120.31,115.20,114.42,69.51,48.19,21.99,10.58;EI-MS,m/z(%):350(M+,10),306(2),
291(1),264(100),220(20),193(5),158(5),131(50),105(15),90(6),77(45),51(5).[0094] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(A4):
[0095]
[0096] 淡黄色晶体,收率31.3%,m.p.199.1-200.5℃;IR(KBr,cm-1)v:3034,2975,1757,1731,1616,1598,1570,1450,1365,1345,1278,1186,1169,746,737;1H NMR(400MHz,DMSO-d6)δ(ppm):7.95(d,J=7.0Hz,1H),7.67(d,J=7.3Hz,1H),7.42-7.33(m,2H),7.28(t,J=
7.6Hz,2H),7.05(d,J=8.1Hz,2H),6.94(t,J=7.1Hz,1H),5.53(s,1H),5.18(s,1H),5.11(dt,J=12.3,6.1Hz,1H),1.32(d,J=3.3Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):
151.10,147.54,145.64,142.77,131.24,130.16,125.62(d,J=15.9Hz),123.01,120.30,+
115.17,114.41,72.61,48.14,22.00;EI-MS,m/z(%):350(M ,5),306(5),291(1),264(100),220(16),193(5),158(5),131(46),105(12),90(7),77(36),51(7).[0097] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯(A5):
[0098]
[0099] 淡黄色晶体,收率32.7%,m.p.171.9-174.0℃;IR(KBr,cm-1)v:2962,2871,1785,1711,1619,1596,1574,1451,1362,1275,1255,1175,742;1H NMR(400MHz,DMSO-d6)δ(ppm):
7.96(d,J=8.0Hz,1H),7.68(d,J=6.9Hz,1H),7.43-7.34(m,2H),7.29(t,J=7.8Hz,2H),
7.07(d,J=8.2Hz,2H),6.94(t,J=7.3Hz,1H),5.54(s,1H),5.17(s,1H),4.32(t,J=
6.4Hz,2H),1.71-1.59(m,2H),1.45-1.30(m,2H),0.90(t,J=7.4Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.60,151.14,147.52,145.64,142.79,131.24,130.16,125.64(d,J=
16.3Hz),123.06,120.32(s),115.21,114.44,67.82,48.19,30.56,18.89,13.96;EI-MS,m/+
z(%):364(M ,6),320(2),291(1),264(100),220(12),158(5),131(40),105(10),77(31),
57(10).
[0100] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(A6):
[0101]
[0102] 无色晶体,收率30.3%,m.p.171.3-174.5℃;IR(KBr,cm-1)v:3028,2972,1743,1616,1595,1572,1449,1363,1272,1249,1166,748,739;1H NMR(400MHz,DMSO-d6)δ(ppm):
7.97(d,J=6.7Hz,1H),7.68(d,J=7.6Hz,1H),7.42-7.33(m,2H),7.29(t,J=7.8Hz,2H),
7.08(d,J=8.1Hz,2H),6.94(t,J=7.2Hz,1H),5.57(s,1H),5.18(s,1H),4.12(d,J=
6.2Hz,2H),2.06-1.87(m,1H),0.92(d,J=6.6Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):
151.59,151.14,147.52,145.66,142.80,131.25,130.16,125.65(d,J=16.2Hz),123.07,
120.32,115.22,114.45,73.63,48.27,27.83,19.09;EI-MS,m/z(%):364(M+,5),291(1),
264(100),220(60),193(21),158(6),131(40),105(10),91(10),77(45),57(25),45(5).[0103] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(A7):
[0104]
[0105] 淡黄色晶体,收率37.3%,m.p.185.7-189.2℃;1R(KBr,cm-1)v:2949,2920,2850,1
1750,1615,1597,1588,1452,1364,1265,1177,1166,743,734;H NMR(400MHz,DMSO-d6)δ(ppm):7.98(d,J=7.3Hz,1H),7.71(d,J=7.6Hz,1H),7.49(q,J=7.7Hz,2H),7.43-7.38(m,2H),7.37-7.28(m,5H),7.21(d,J=8.5Hz,2H),6.98(t,J=7.2Hz,1H),5.54(s,1H),
5.33(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.09,150.73,150.41,147.31,145.43,
142.79,131.20,130.29(d,J=5.4Hz),130.20,127.03,125.86(d,J=14.5Hz),123.30,
122.07,120.45,115.34,114.46,48.09;EI-MS,m/z(%):384(M+,63),339(22),291(5),264(30),220(50),193(15),163(10),131(10),118(10),105(55),77(100),51(12).[0106] 1-氧代-3-苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(A8):
[0107]
[0108] 褐色晶体,收率36.5%,m.p.165.0-166.1℃;IR(KBr,cm-1)v:2955,2914,2875,2843,1789,1614,1594,1565,1489,1452,1362,1267,1184,1132,754,735;1H NMR(400MHz,DMSO-d6)δ(ppm):8.01-7.94(m,1H),7.68(dd,J=6.1,2.6Hz,1H),7.47(d,J=7.1Hz,2H),
7.44-7.31(m,5H),7.28(dd,J=8.6,7.5Hz,2H),7.09(d,J=8.0Hz,2H),6.94(t,J=7.3Hz,
1H),5.57(s,1H),5.42(s,2H),5.18(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.56,
151.13,147.46,145.61,142.79,135.75,131.23,130.17,128.96,128.76,128.24,125.69(d,J=15.2Hz),123.15,120.34,115.28,114.45,69.21,48.22;EI-MS,m/z(%):398(M+,
1),354(25),264(15),220(25),193(7),131(10),118(2),91(100),77(42),65(7),51(7).[0109] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(B1):
[0110]
[0111] 黄色粉末,收率32.3%,m.p.144.5-146.8℃;IR(KBr,cm-1)v:2956,1789,1610,1559,1490,1437,1364,1252,1187,741;1H NMR(400MHz,DMSO-d6)δ(ppm):7.99-7.90(m,
1H),7.73-7.66(m,1H),7.44-7.37(m,2H),7.34(d,J=9.1Hz,2H),7.13(d,J=9.1Hz,2H),
5.57(s,1H),5.18(s,1H),3.91(s,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.97,150.86,
146.4,145.33,142.75,131.23,129.98,127.20,125.74(d,J=16.8Hz),120.37,117.14,
114.43,55.13,48.22;EI-MS,m/z(%):356(M+,78),311(70),297(5),254(16),220(10),
158(14),139(52),130(20),111(100),90(19),75(18),59(15),45(3).
[0112] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(B2):
[0113]
[0114] 黄色固体,收率34.8%,m.p.162.1-163.8℃;IR(KBr,cm-1)v:3084,2978,1790,1617,1565,1488,1450,1364,1248,1233,1185,742;1H NMR(400MHz,DMSO-d6)δ(ppm):8.02-
7.92(m,1H),7.73-7.66(m,1H),7.44-7.30(m,4H),7.12(d,J=9.0Hz,2H),5.58(s,1H),
5.18(s,1H),4.37(q,J=7.0Hz,2H),1.31(t,J=7.1Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.39,150.89,146.47,145.38,142.76,131.23,129.97,127.15,125.70(d,J=
16.7Hz),120.35,117.09,114.43,64.41,48.20,14.54;EI-MS,m/z(%):370(M+,32),326(15),298(100),254(20),227(7),159(11),141(15),131(100),111(80),90(18),75(16),
63(7),45(6).
[0115] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d.[1,2,4]三嗪-2(1H)-甲酸丙酯(B3):
[0116]
[0117] 黄色固体,收率34.1%,m.p.150.3-152.1℃;IR(KBr,cm-1)v:2981,2952,1790,1
1613,1570,1493,1452,1365,1251,1183,743;H NMR(400MHz,DMSO-d6)δ(ppm):8.00-7.94(m,1H),7.70(dd,J=6.3,2.4Hz,1H),7.43-7.37(m,2H),7.37-7.31(m,2H),7.13(dd,J=
9.7,2.7Hz,2H),5.59(s,1H),5.19(s,1H),4.29(t,J=6.5Hz,2H),1.77-1.60(m,2H),0.93(t,J=7.4Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.44,150.91,146.48,145.39,
142.77,131.23,129.98,127.12,125.72(d,J=16.5Hz),120.36,117.08,114.46,69.63,
48.24,21.98,10.59;EI-MS,m/z(%):384(M+,12),340(3),298(100),254(10),220(3),168(5),158(7),131(73),111(35),90(10),75(7),51(1).
[0118] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(B4):
[0119]
[0120] 无色晶体,收率35.3%,m.p.165.5-168.3℃;IR(KBr,cm-1)v:2994,1787,1617,1591,1569,1447,1362,1262,1180,744;1H NMR(400MHz,DMSO-d6)δ(ppm):7.98-7.93(m,
1H),7.73-7.63(m,1H),7.43-7.37(m,2H),7.34(d,J=8.8Hz,2H),7.09(d,J=8.9Hz,2H),
13
5.56(s,1H),5.14(s,1H),5.15-5.02(m,1H),1.33(d,J=3.2Hz,6H);C NMR(101MHz,DMSO-d6)δ(ppm):150.91,146.51,145.40,142.77,131.23,129.99,127.09,125.70(d,J=
16.5Hz),120.35,117.05,114.45,72.78,48.21,22.00;EI-MS,m/z(%):384(M+,5),340(2),325(2),298(100),254(7),220(2),168(5),158(6),131(70),111(31),90(10),75(7),
51(2).
[0121] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(B5):
[0122]
[0123] 无色晶体,收率32.3%,m.p.158.0-159.7℃;IR(KBr,cm-1)v:2965,1786,1619,1594,1573,1451,1366,1261,1199,741;1H NMR(400MHz,DMSO-d6)δ(ppm):8.00-7.93(m,
1H),7.72-7.65(m,1H),7.43-7.37(m,2H),7.35(d,J=7.9Hz,2H),7.11(d,J=8.9Hz,2H),
5.57(s,1H),5.17(s,1H),4.12(d,J=6.3Hz,2H),1.98(tq,J=12.7,6.3Hz,1H),0.93(d,J=6.7Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.43,150.90,146.49,145.41,142.78,
131.24,129.96,127.13,125.69(d,J=16.1Hz),120.34,117.08,114.48,73.73,48.30,
27.80,19.08;EI-MS,m/z(%):398(M+,8),298(100),254(15),227(6),158(5),139(10),
131(65),111(30),90(9),57(36),51(3).
[0124] 1-氧代-3-对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(B6):
[0125]
[0126] 淡黄色晶体,收率36.0%,m.p.175.5-177.6℃;IR(KBr,cm-1)v:3039,2914,1751,1615,1590,1570,1450,1363,1263,1178,739;1H NMR(400MHz,DMSO-d6)δ(ppm):8.06-7.94(m,1H),7.74(d,J=6.8Hz,1H),7.52(t,J=7.8Hz,2H),7.41(dt,J=17.1,7.6Hz,7H),7.29(d,J=9.1Hz,2H),5.68(s,1H),5.37(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):150.76,
150.24,146.25,145.17,142.76,131.19,130.17(d,J=15.1Hz),127.60-127.43(m),
127.21(d,J=32.3Hz),125.90(d,J=14.5Hz),122.05,120.47,117.25,114.49,48.13;EI-+
MS,m/z(%):418(M,76),373(20),325(5),298(28),254(100),227(28),220(15),193(7),
163(27),139(67),131(15),111(100),77(47),70(96),51(15).
[0127] 1-氧代-3对氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(B7):
[0128]
[0129] 无色晶体,收率33.7%,m.p.158.5-161.2℃;IR(KBr,cm-1)v:2959,1747,1615,1547,1492,1449,1356,1258,1186,741;1H NMR(400MHz,DMSO-d6)δ(ppm):7.97(dd,J=6.3,
2.6Hz,1H),7.70(dd,J=6.2,2.5Hz,1H),7.51-7.27(m,9H),7.14(d,J=9.1Hz,2H),5.59(s,1H),5.42(s,2H),5.20(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.40,150.90,
146.43,145.35,142.77,135.66,131.21,129.98,128.97,128.78,128.27,127.21,125.76(d,J=15.7Hz),120.38,117.16,114.48,69.33,48.25;EI-MS,m/z(%):432(M+,1),418(1),388(15),298(18),254(25),221(13),193(2),177(5),131(15),111(26),91(100),65(8),51(6).
[0130] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(C1):
[0131]
[0132] 无色晶体,收率37.3%,m.p.171.0-173.2℃;IR(KBr,cm-1)v:3032,2955,2917,2846,1792,1617,1574,1508,1454,1366,1254,1189,745;1H NMR(400MHz,DMSO-d6)δ(ppm):
7.95(d,J=7.8Hz,1H),7.68(d,J=7.0Hz,1H),7.38(p,J=7.3Hz,2H),7.08(d,J=8.3Hz,
2H),6.96(d,J=8.3Hz,2H),5.48(s,1H),5.14(s,1H),3.89(s,3H),2.16(d,J=19.4Hz,
3H);13C NMR(101MHz,DMSO-d6)δ(ppm):152.12,151.12,145.65,145.18,142.77,132.22,
131.22,130.56,125.65(d,J=16.6Hz),120.31,115.32,114.36,55.0,48.39,20.35;EI-MS,m/z(%):336(M+,70),291(50),277(6),234(20),220(5),207(5),145(7),130(7),119(40),103(5),91(100),65(15),45(1).
[0133] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(C2):
[0134]
[0135] 无色晶体,收率35.3%,m.p.178.1-180.0℃;IR(KBr,cm-1)v:3035,2907,1783,1617,1565,1508,1450,1360,1259,1183,746;1H NMR(400MHz,DMSO-d6)δ(ppm):7.95(dd,J=6.3,2.5Hz,1H),7.67(dd,J=6.3,2.5Hz,1H),7.40-7.32(m,2H),7.08(d,J=8.5Hz,2H),
6.96(d,J=8.7Hz,2H),5.48(s,1H),5.14(s,1H),4.36(q,J=7.1Hz,2H),2.13(s,3H),1.30(t,J=7.1Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.57,151.15,145.68,145.23,
142.77,132.18,131.22,130.56,125.62(d,J=16.6Hz),120.30,115.28,114.38,64.22,
48.37,20.36,14.58;EI-MS,m/z(%):350(M+,25),306(12),278(75),234(40),207(12),
159(5),148(5),131(41),119(37),103(9),91(100),70(11),65(15),45(7).[0136] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(C3):
[0137]
[0138] 无色晶体,收率34.2%,m.p.145.0-146.8℃;IR(KBr,cm-1)v:3055,2949,1790,1
1617,1569,1514,1450,1367,1253,1181,743;H NMR(400MHz,DMSO-d6)δ(ppm):8.01-7.90(m,1H),7.75-7.62(m,1H),7.44-7.29(m,2H),7.08(d,J=8.4Hz,2H),6.96(d,J=8.7Hz,
2H),5.49(s,1H),5.12(s,1H),4.28(t,J=6.5Hz,2H),2.13(s,3H),1.77-1.60(m,2H),0.92(t,J=7.4Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.65,151.17,145.70,145.25,
142.78,132.17,131.23,130.55,125.61(d,J=16.4Hz),120.30,115.28,114.40,69.45,
48.40,22.00,20.36,10.59;EI-MS,m/z(%):364(M+,16),320(2),278(100),234(35),220(5),207(10),159(5),148(6),131(50),119(17),91(62),70(12),45(3).
[0139] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(C4):
[0140]
[0141] 黄色晶体粉末,收率28.6%;m.p.165.7-167.6℃;IR(KBr,cm-1)v:3045,2963,1788,1630,1547,1521,1458,1372,1246,1179,742;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(d,1H),7.67(d,J=6.1,2.5Hz,1H),7.46-7.30(m,2H),7.08(d,J=8.4Hz,2H),6.95(d,J=
13
8.5Hz,2H),5.47(s,1H),5.21-4.98(m,2H),2.13(s,3H),1.32(d,J=5.2Hz,6H);C NMR(101MHz,DMSO-d6)δ(ppm):151.18(s),151.10(s),145.72(s),145.29(s),142.80(s),
132.13(s),131.25(s),130.55(s),125.58(d,J=16.2Hz),120.29(s),115.25(s),114.40(s),72.52(s),48.38(s),22.01(s),20.36(s);EI-MS,m/z(%):364(M+,5),322(45),278(70),236(50),218(50),207(10),176(52),132(100),119(25),91(81),65(20),45(11).[0142] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯(C5):
[0143]
[0144] 无色晶体,收率33.7%,m.p.137.5-139.7℃;IR(KBr,cm-1)v:3064,2952,1784,1
1613,1572,1511,1447,1364,1260,1187,742;H NMR(400MHz,DMSO-d6)δ(ppm):7.98-7.89(m,1H),7.67(dd,J=6.2,2.7Hz,1H),7.44-7.31(m,2H),7.07(d,J=8.5Hz,2H),6.95(d,J=8.7Hz,2H),548(s,1H),5.13(s,1H),4.32(t,J=6.5Hz,2H),2.13(s,3H),1.70-1.59(m,
2H),1.44-1.29(m,2H),0.89(t,J=7.4Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.64,
151.17,145.69,145.25,142.78,132.16,130.54,125.61(d,J=16.3Hz),120.29,115.27,
114.40,67.76,48.38,30.56,20.36,18.89,13.97;EI-MS,m/z(%):378(M+,11),278(100),
234(37),207(10),148(5),131(45),119(15),91(50),77(3),56(15),51(2).[0145] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(C6):
[0146]
[0147] 无色晶体,收率35.3%,m.p.115.7-116.8℃;IR 3180,2955,2923,1785,1620,1572,1511,1450,1364,1264,1196,744;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(dd,J=6.3,
2.6Hz,1H),7.67(dd,J=6.1,2.6Hz,1H),7.37(pd,J=7.4,3.7Hz,2H),7.08(d,J=8.5Hz,
2H),6.95(d,J=8.7Hz,2H),5.49(s,1H),5.13(s,1H),4.11(d,J=6.5Hz,2H),2.14(s,3H),
2.03-1.89(m,1H),0.93(d,J=6.7Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.64,
151.17,145.72,145.26,142.79,132.18,131.24,130.55,125.62(d,J=16.3Hz),120.29,
115.28,114.42,73.57,27.83,20.37,19.43,19.11;EI-MS,m/z(%):378(M+,11),278(100),234(30),207(7),148(5),131(40),119(11),91(42),77(3),57(16),51(2).[0148] 1-氧代-3-对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(C7):
[0149]
[0150] 无色晶体,收率37.3%,m.p.184.161.2-185.6℃;IR(KBr,cm-1)v:3003,2895,1749,1569,1505,1453,1367,1265,1187,751,740;1H NMR(400MHz,DMSO-d6)δ(ppm):7.98(dd,J=6.5,2.5Hz,1H),7.71(dd,J=6.2,2.2Hz,1H),7.54-7.46(m,2H),7.40(ddd,J=
5.9,5.3,3.7Hz,2H),7.35(t,J=7.0Hz,3H),7.16-7.07(m,4H),5.58(s,1H),5.32(s,1H),
13
2.16(s,3H);C NMR(101MHz,DMSO-d6)δ(ppm):151.12,150.73,145.49,145.04,132.43,
130.70,130.26,127.01,125.82(d,J=14.3Hz),122.06,120.42,115.40,114.44,48.29,
20.40;EI-MS,m/z(%):398(M+,65),353(12),278(25),234(100),220(10),207(30),163(16),119(50),103(7),91(100),70(55),51(7).
[0151] 1-氧代-3对甲基苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(C8):
[0152]
[0153] 无色晶体,收率36.1%,m.p.173.5-175.4℃;IR(KBr,cm-1)v:3010,1736,1617,1572,1505,1450,1357,1269,1184,750;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(dd,J=6.3,
2.7Hz,1H),7.68(dd,J=5.9,2.6Hz,1H),7.47(d,J=7.3Hz,2H),7.42(d,J=6.8Hz,2H),
7.39-7.31(m,3H),7.07(d,J=8.5Hz,2H),6.97(d,J=8.6Hz,2H),5.50(s,1H),5.41(s,
2H),5.17(s,1H),2.13(s,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.60,151.16,145.67,
145.19,142.79,135.77,132.27,131.22,130.56,128.96,128.75,128.25,125.65(d,J=
15.3Hz),120.31,115.35,114.43,69.16,48.41,20.37;EI-MS,m/z(%):412(M+,2),368(16),277(15),234(15),221(7),207(3),119(25),91(100),65(10),51(2).[0154] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(D1):
[0155]
[0156] 黄色粉末,收率31.1%,m.p.159.9-161.5℃;IR(KBr,cm-1)v:3084,2970,1784,1507,1363,1031,751,657;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(d,J=7.0Hz,1H),7.67(t,J=13.3Hz,1H),7.49-7.29(m,2H),7.23-6.99(m,4H),5.52(s,1H),5.16(s,1H),4.37(q,J=6.9Hz,2H),1.40-1.24(m,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.47,157.20,
151.49,150.99,145.52,143.96(d,J=2.1Hz),142.78,131.28,125.70(d,J=16.7Hz),
125.62,120.36,117.13(d,J=8.1Hz),116.90,116.68,114.44,64.35,48.54,14.5;EI-MS,m/z(%):354(M+,25),310(15),282(100),238(27),211(8),184(1),158(11),138(11),131(78),103(11),95(100),75(12),63(5),45(4).
[0157] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(D2):
[0158]
[0159] 黄色晶体,收率40.8%,m.p.167.9-170.1℃;IR(KBr,cm-1)v:3069,2964,1787,1507,1367,1032,987,842,742;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(dd,J=6.1,2.0Hz,
1H),7.75-7.63(m,1H),7.50-7.32(m,2H),7.12(p,J=9.3Hz,4H),5.51(s,1H),5.19(s,
1H),4.28(t,J=6.4Hz,2H),1.68(dq,J=13.7,6.9Hz,2H),1.06-0.76(m,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.51,157.13,151.57,150.99,145.55,143.97(d,J=2.2Hz),
142.80,131.25,125.67(d,J=16.2Hz),120.34,117.12(d,J=8.0Hz),116.88,116.65,+
114.46,69.57,48.54,21.98,10.57;EI-MS,m/z(%):368(M ,12),324(3),309(1),282(100),238(12),211(5),184(1),158(7),131(65),110(10),95(40),63(2),50(1).[0160] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(D3):
[0161]
[0162] 淡黄色粉末,收率27.6%,m.p.171.2-172.7℃;IR(KBr,cm-1)v:3078,2979,1781,1506,1093,833,736,654;1H NMR(400MHz,DMSO-d6)δ(ppm):7.97(d,J=7.2Hz,1H),7.69(d,J=7.4Hz,1H),7.45-7.33(m,2H),7.20-7.04(m,4H),5.38(s,1H),5.21(s,1H),5.11(dt,J=12.3,6.1Hz,1H),1.32(d,J=6.9Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.49,
157.11,151.02,145.55,144.00(d,J=2.1Hz),142.79,131.25,125.74,125.58,120.34,
117.12,117.04,116.89,116.66,114.45,72.70,48.54,21.99;EI-MS,m/z(%):368(M+,5),
324(3),309(1),282(100),238(11),211(6),184(1),158(6),131(60),110(10),37(37),70(7),64(2),45(1).
[0163] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸正丁酯(D4):
[0164]
[0165] 白色粉末,收率30.7%,m.p.158.0-160.2℃;IR(KBr,cm-1)v:3069,2958,1786,1507,1031,832,764,747;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(dd,J=6.4,2.3Hz,1H),
7.68(d,J=6.3,2.4Hz,1H),7.46-7.30(m,2H),7.23-7.01(m,4H),5.51(s,1H),5.19(s,
1H),4.32(t,J=6.4Hz,2H),1.76-1.57(m,2H),1.37(dq,J=14.6,7.4Hz,2H),0.90(t,J=
7.4Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.51,157.12,151.55,151.00,145.33,
143.97(d,J=2.1Hz),142.79,131.24,125.68(d,J=16.3Hz),120.34,117.11(d,J=
7.9Hz),116.68,116.65,114.46,67.88,48.52,30.54,18.89,13.95;EI-MS,m/z(%):382(M+,10),309(1),282(100),238(15),211(5),184(1),158(5),131(55),123(12),95(30),75(5),57(12),51(1).
[0166] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丁酯(D5):
[0167]
[0168] 淡黄色粉末,收率31.7%,m.p.180.3-182.2℃;IR(KBr,cm-1)v:3066,2961,1787,1505,1032,989,853,741;1H NMR(400MHz,DMSO-d6)δ(ppm):7.98(dd,J=6.4,2.4Hz,1H),
7.68(d,J=6.2,2.2Hz,1H),7.49-7.30(m,2H),7.26-7.03(m,4H),5.45(s,1H),5.35(s,
1H),4.11(d,J=6.4Hz,2H),2.10-1.89(m,1H),1.01-0.85(d,J=6.7Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.51,157.13,151.54,150.99,145.56,143.91(d,J=1.8Hz),
142.80,131.25,125.76,125.60,120.34,117.20(d,J=8.1Hz),116.89,116.66,114.48,
73.68,48.61,27.81,19.09;EI-MS,m/z(%):382(M+,8),338(1),309(1),282(100),238(15),211(5),184(1),158(6),131(50),123(10),95(26),75(5),57(21),51(1).[0169] 1-氧代-3-对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(D6):
[0170]
[0171] 褐色粉末,收率30.10%,m.p.199.3-201.2℃;IR(KBr,cm-1)v:3066,2961,1752,1506,1178,1160,792,740;1H NMR(400MHz,DMSO-d6)δ(ppm):8.02(d,J=6.3Hz,1H),7.73(d,J=5.6Hz,1H),7.52(d,J=7.7Hz,2H),7.39(dd,J=16.5,8.6Hz,5H),7.28(s,2H),7.19(d,J=7.8Hz,2H),5.64(s,1H),5.37(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.66,
157.28,150.95,150.73,150.37,145.33,143.75(d,J=2.1Hz),142.80,131.21,130.25,
127.04,125.88(d,J=14.3Hz),122.07,120.46,117.31(d,J=8.0Hz).117.02,116.79,+
114.50,48.40;EI-MS,m/z(%):402(M,82),357(30),309(5),282(35),238(55),211(16),
188(3),163(10),145(5),123(100),95(95),77(32),70(35),51(6).
[0172] 1-氧代-3对氟苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(D7):
[0173]
[0174] 淡黄色粉末,收率38.1%,m.p.170.5-172.6℃;IR(KBr,cm-1)v:3068,3016,1738,1504,1264,829,750,738;1H NMR(400MHz,DMSO-d6)δ(ppm):1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(d,J=6.0Hz,1H),7.69(d,J=6.5Hz,1H),7.46(d,J=6.8Hz,2H),7.40(dd,J=
12.6,5.1Hz,5H),7.12(d,J=5.0Hz,4H),5.52(s,1H),5.41(s,2H),5.16(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):159.56,157.17,151.52,150.99,145.51,143.91(d,J=1.8Hz),
142.80,135.71,131.24,128.97,128.77,128.26,125.72(d,J=15.2Hz),120.37,117.20(d,J=8.1Hz),116.89,116.67,114.49,69.28,48.54;EI-MS,m/z(%):416(M+,1),372(16),281(5),238(10),221(10),211(3),123(18),95(25),91(100),65(5),51(1).[0175] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(E1):
[0176]
[0177] 黄色粉末,收率34.2%;m.p.151.5-153.4℃;IR(KBr,cm-1)v:2988,2900,1789,1715,1616,1570,1490,1362,1248,1185,1033,759,742;1H NMR(400MHz,DMSO-d6)δ(ppm):
7.96(d,J=7.2Hz,1H),7.69(d,J=7.1Hz,1H),7.47(d,J=8.0Hz,2H),7.43-7.33(m,2H),
7.07(d,J=8.0Hz,2H),5.57(s,1H),5.18(s,1H),4.38(dd,J=13.8,6.8Hz,2H),1.31(t,J=6.9Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.35(s),146.92(s),145.34(s),132.86(s),131.22(s),125.72(d,J=16.6Hz),120.36(s),117.50(s),115.03(s),114.43(s),+
64.42(s),48.15(s),14.56(s);EI-MS,m/z(%):416(M ,20),372(13),344(77),300(8),
273(3),233(3),220(6),200(6),183(31),155(55),131(100),103(25),90(26),70(10),50(5).
[0178] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸丙酯(E2):
[0179]
[0180] 土褐色粉末,收率35.1%;m.p.171.3-173.7℃;IR(KBr,cm-1)v:2974,2883,2158,2024,1790,1569,1490,1451,1250,1235,1166,979,824,743;1H NMR(400MHz,DMSO-d6)δ(ppm):7.97(d,J=7.0Hz,1H),7.69(d,J=7.3Hz,1H),7.47(d,J=8.4Hz,2H),7.44-7.33(m,2H),7.07(d,J=8.3Hz,2H),5.57(s,1H),5.18(s,1H),4.29(t,J=6.3Hz,2H),1.69(dd,J=13.8,6.9Hz,2H),0.93(t,J=7.3Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.63(s),
151.14(s),146.92(s),145.36(s),142.77(s),132.85(s),131.23(s),125.71(d,J=
16.7Hz),120.36(s),117.49(s),115.01(s),114.45(s),69.64(s),48.19(s),21.98(s),
10.59(s);EI-MS,m/z(%):430(M+,10),384(2),342(91),300(25),273(7),233(3),219(8),183(12),155(26),131(100),103(21),76(23),70(50),45(13).
[0181] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸异丙酯(E3):
[0182]
[0183] 黄晶粉,收率29.7%;m.p.182.1-183.9℃;IR(KBr,cm-1)v:2983,2900,1745,1488,1363,1196,1180,1091,762,743;1H NMR(400MHz,DMSO-d6)δ(ppm):8.04-7.90(m,1H),7.77-
7.64(m,1H),7.47(d,J=8.9Hz,2H),7.43-7.33(m,2H),7.06(d,J=8.9Hz,2H),7.02-7.01(m,1H),5.56(s,1H),5.19(s,1H),5.11(dt,J=12.3,6.2Hz,1H),1.33(d,J=2.2Hz,6H);13C NMR(101MHz,DMSO-d6)δ(ppm):150.90(s),146.96(s),145.38(s),132.87(s),131.24(s),
125.70(d,J=16.4Hz),120.35(s),117.46(s),114.99(s),114.45(s),72.79(s),48.16(s),22.00(s);EI-MS,m/z(%):430(M+,5),386(3),342(100),300(12),273(2),233(1),
220(5),185(10),155(26),131(100),103(20),90(25),70(18),46(10).
[0184] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(E4):
[0185]
[0186] 褐色粉末,收率33.0%;m.p.220.8-223.6℃;IR(KBr,cm-1)v:3052,1753,1640,1609,1487,1264,1178,1149,1008,818,744,689;1H NMR(400MHz,DMSO-d6)δ(ppm):7.99(d,J=6.8Hz,1H),7.73(d,J=6.5Hz,1H),7.50(d,J=7.4Hz,4H),7.41(d,J=3.9Hz,2H),7.35(d,J=6.7Hz,3H),7.22(d,J=7.9Hz,2H),5.66(s,1H),5.35(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):150.83(s),150.71(s),150.22(s),146.72(s),145.17(s),142.78(s),132.99(s),131.21(s),130.26(s),127.06(s),125.93(d,J=14.3Hz),122.05(s),120.48(s),
117.66(s),115.29(s),114.51(s),48.09(s);EI-MS,m/z(%):464(M+,71),419(20),369(5),342(38),300(65),273(17),251(6),220(27),207(11),183(30),155(47),131(30),
103(26),90(32),70(100),51(30).
[0187] 1-氧代-3-对溴苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(E5):
[0188]
[0189] 淡黄色粉末,收率37.6%;m.p.179.4-188.2℃;IR(KBr,cm-1)v:3028,1751,1643,1588,1479,1238,1147,826,743;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(d,J=6.8Hz,1H),
7.69(d,J=8.6Hz,1H),7.46(d,J=7.2Hz,4H),7.42(d,J=6.9Hz,2H),7.38(dd,J=7.4,
4.8Hz,3H),7.07(d,J=9.0Hz,2H),5.57(s,1H),5.41(s,2H),5.17(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.74(s),151.16(s),146.91(s),145.34(s),142.78(s),135.66(s),
132.88(s),131.23(s),128.98(s),128.79(s),128.31(s),125.79(d,J=14.8Hz),120.39(s),117.60(s),115.13(s),114.51(s),69.37(s),48.23(s);EI-MS,m/z(%):478(M+,1),
464(2),434(10),392(1),377(2),342(5),312(3),300(5),273(),221(13),183(10),155(10),131(8),103(8),91(100),65(8),51(1).
[0190] 1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(F1):
[0191]
[0192] 黄色粉末,收率28.9%;m.p.196.2-198.5℃;IR(KBr,cm-1)v:2973,2889,1774,1750,1468,1437,1248,1191,1096,1041,762,754;1H NMR(400MHz,DMSO-d6)δ(ppm):7.96(d,J=6.8Hz,1H),7.70(d,J=7.0Hz,1H),7.40(td,J=12.4,7.9Hz,2H),7.35-7.27(m,
1H),7.23(d,J=1.8Hz,1H),7.03(t,J=9.4Hz,2H),5.63(s,1H),5.14(s,1H),3.90(s,3H)
13
;C NMR(101MHz,DMSO-d6)δ(ppm):151.87(s),150.85(s),149.01(s),145.27(s),142.75(s),134.90(s),131.90(s),131.20(s),125.80(d,J=17.3Hz),123.00(s),120.42(s),
115.17(s),114.47(s),113.83(s),55.21(s),48.07(s);EI-MS,m/z(%):358(M+,20),356(55),311(70),297(2),254(18),233(1),227(8),205(3),189(3),158(17),139(31),111(100),90(20),75(18),59(6),45(5).
[0193] 1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸乙酯(F2):
[0194]
[0195] 砖红色色粉末,收率31.4%;m.p.161.0-163.1℃;IR(KBr,cm-1)v:2975,2882,1
2158,1780,1748,1473,1452,1251,1203,1182,1088,1034,762,745,656;H NMR(400MHz,DMSO-d6)δ(ppm):7.98(d,J=6.5Hz,1H),7.70(d,J=6.5Hz,1H),7.48-7.36(m,2H),7.32(t,J=7.7Hz,1H),7.23(s,1H),7.03(t,J=9.4Hz,2H),5.66(s,1H),5.19(s,1H),4.39(q,
2H),1.31(t,J=6.3Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.32(s),150.88(s),
149.06(s),145.32(s),142.77(s),134.88(s),131.90(s),131.24(s),125.76(d,J=
16.6Hz),122.95(s),120.40(s),115.14(s),114.49(s),113.80(s),64.49(s),48.07(s),
14.55(s);EI-MS,m/z(%):370(M+,12),326(15),298(100),254(25),227(13),158(23),
131(85),111(100),90(31),75(30),63(10),46(65).
[0196] 1-氧代-3-间氯苯基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苄酯(F3):
[0197]
[0198] 淡黄色粉,收率37.8%;m.p.178.6-180.2℃;IR(KBr,cm-1)v:3030,2899,1743,1593,1572,1450,1365,1284,1259,1162,1146,741,729;1HNMR(400MHz,DMSO-d6)δ(ppm):
7.98(d,J=6.8Hz,1H),7.71(d,J=7.2Hz,1H),7.48(d,J=7.1Hz,2H),7.43(d,J=6.9Hz,
2H),7.40(d,J=3.7Hz,3H),7.34-7.28(m,1H),7.23(s,1H),7.06(d,J=8.2Hz,1H),7.01(d,J=7.8Hz,1H),5.68(s,1H),5.44(s,2H),5.21(s,1H);13C NMR(101MHz,DMSO-d6)δ(ppm):151.32(s),150.87(s),148.98(s),145.30(s),142.79(s),135.69(s),134.90(s),
131.85(s),131.23(s),128.97(s),128.79(s),128.26(s),125.78(d,J=15.2Hz),123.01(s),120.40(s),115.22(s),114.53(s),113.83(s),69.37(s),48.09(s);EI-MS,m/z(%):
432(M+,1),390(3),388(10),346(1),298(10),254(11),227(6),221(12),192(2),177(3),
131(10),111(20),91(100),65(7),51(5).
[0199] 1-氧代-3-苯基-4-甲基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸甲酯(G1):
[0200]
[0201] 淡黄色粉末,收率26.1%;m.p.120.0-121.9℃;IR(KBr,cm-1)v:2954,2871,1789,1755,1720,1595,1452,1347,1263,1185,1057,745,691;1H NMR(400MHz,DMSO-d6)δ(ppm):
8.00(d,J=7.8Hz,1H),7.68(d,J=7.0Hz,1H),7.44-7.35(m,2H),7.30(t,J=7.9Hz,2H),
7.13(d,J=8.1Hz,2H),6.97(t,J=7.2Hz,1H),5.84(dd,J=13.4,6.5Hz,1H),3.93(s,3H),
1.70(d,J=6.8Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):153.56(s),152.70(s),147.58(s),145.33(s),142.70(s),131.06(s),130.23(s),125.82(d,J=17.5Hz),123.46(s),
120.42(s),115.69(s),114.63(s),55.31(s),53.90(s),17.83(s);EI-MS,m/z(%):336(M+,45),321(23),291(1),277(75),263(20),234(17),220(16),204(15),192(1),171(3),
146(80),118(17),105(30),92(18),77(100),51(15),45(1).
[0202] 1-氧代-3-苯基-4-甲基-3,4-二氢苯并[4,5]咪唑并[1,2-d][1,2,4]三嗪-2(1H)-甲酸苯酯(G2):
[0203]
[0204] 褐色晶体,收率36.7%;m.p.196.1-197.3℃;IR(KBr,cm-1)v:2991,2883,1774,1446,1357,1260,1178,1049,756,741,693;1H NMR(400MHz,DMSO-d6)δ(ppm):8.10-8.00(m,
1H),7.73(d,J=7.1Hz,1H),7.51(t,J=7.8Hz,2H),7.43(dd,J=13.0,6.2Hz,2H),7.36(t,J=8.0Hz,5H),7.28(d,J=8.2Hz,2H),7.01(t,J=7.1Hz,1H),5.95(q,J=6.6Hz,1H),1.87(d,J=6.8Hz,3H);13C NMR(101MHz,DMSO-d6)δ(ppm):153.54(s),150.99(s),150.60(s),
147.41(s),145.14(s),142.75(s),131.08(s),130.34(d,J=4.6Hz),127.14(s),125.95(d,J=14.2Hz),123.62(s),121.97(s),120.50(s),115.21(d,J=102.3Hz),114.64-
114.51(m),53.88(s),17.90(s);EI-MS,m/z(%):398(M+,65),383(27),339(37),277(15),
263(30),234(10),220(15),193(2),171(2),143(12),118(18),105(81),77(100),70(10),
51(10).
[0205] 用途实施例
[0206] 实施例2:本发明的苯并咪唑并三嗪酮类化合物(I)对植物病原真菌的杀菌活性测定
[0207] 采用菌丝生长速率法测定了苯并咪唑并三嗪酮类化合物(I)中的A、B、C、D、E、F和G系列化合物对3种供试植物病原菌草莓灰霉病菌(Botrytis cinerea)、水稻纹枯病菌(Rhizoctonia solani)和辣椒炭疽病菌(Colletotrichum capsici)在50μg/mL浓度下的杀菌活性。
[0208] 测定方法:准确称取4.5mg的待测化合物(包括对照药剂多菌灵)溶于0.5mL甲醇中,加入到89.5mL经灭菌的PSA培养基中,充分摇匀,制成浓度为50μg/mL的含药培养基,将其倒入直径9cm的无菌培养皿中。以加入等量的溶剂制成的培养基为对照。同时以杀菌剂多菌灵制得的浓度为50μg/mL的培养基为药剂对照。用打孔器(内径0.5cm)将生长正常的菌落打孔制取菌饼,用接种针将菌饼接入上述培养基平板中央,在25℃下于培养箱中倒置培养。待对照培养基上的菌落直径长至平板的2/3时测量其直径,每个菌落直径按十字交叉法测量2次,计算其平均值(单位:cm)。各浓度和三种对照均设三个重复。计算药剂处理后的生长抑制率,计算公式如下:
[0209] 抑制率(%)=(溶剂对照菌落直径-处理菌落直径)÷(溶剂对照菌落直径-0.5)×100%
[0210] 苯并咪唑并三嗪酮类化合物(I)对3种供试植物病原菌的生长抑制率测定结果列于表1。
[0211] 表1 苯并咪唑并三嗪酮类化合物(I)对3种植物病原菌的抑制率(50μg/mL)[0212]
[0213] 表1显示,苯并咪唑并三嗪酮类化合物(I)在50μg/mL浓度下对3种供试植物病原菌草莓灰霉病菌、水稻纹枯病菌和辣椒炭疽病菌具有明显的杀菌活性。化合物A1、A8、B1-B7、C1、C2、C4、C5、D2、E1-E5、F1和F2对草莓灰霉病菌的抑制率超过50%,其中化合物A1、B1-B3、C1、C2、E1、E2、F1和F2的抑制率超过60%的,化合物B1和C2的抑制率超过70%。化合物A2、A7、A8、B1-B3、C1-C3、C5、C7、D1、D2、D5、D6、E1-E5、F1-F3对水稻纹枯病菌的抑制超过50%,其中化合物A2、A8、C7、D6、E1、E2、E4、E5、F1和F2的抑制率超过60%。化合物A1、B1、B6、C1、D1-D3、D5、D6、E1、F1和F2对辣椒炭疽病菌的抑制率超过50%,其中化合物B1、D1-D3、F1和F2的抑制率超过60%。
高效检索全球专利

专利汇是专利免费检索,专利查询,专利分析-国家发明专利查询检索分析平台,是提供专利分析,专利查询,专利检索等数据服务功能的知识产权数据服务商。

我们的产品包含105个国家的1.26亿组数据,免费查、免费专利分析。

申请试用

分析报告

专利汇分析报告产品可以对行业情报数据进行梳理分析,涉及维度包括行业专利基本状况分析、地域分析、技术分析、发明人分析、申请人分析、专利权人分析、失效分析、核心专利分析、法律分析、研发重点分析、企业专利处境分析、技术处境分析、专利寿命分析、企业定位分析、引证分析等超过60个分析角度,系统通过AI智能系统对图表进行解读,只需1分钟,一键生成行业专利分析报告。

申请试用

QQ群二维码
意见反馈